An update on biologic treatments for neuromyelitis optica spectrum disorder

References

• Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6:85.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189.
   PubMed Web of Science ®Google Scholar
• Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, et al. The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives. Int J Mol Sci. 2016;17:273.
   PubMed Web of Science ®Google Scholar
• Sechi E, Cacciaguerra L, Chen JJ, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022;13:885218.
   PubMed Web of Science ®Google Scholar
• Yao T, Zeng Q, Xie Y, et al. Clinical analysis of adult MOG antibody-associated cortical encephalitis. Mult Scler Relat Disord. 2022;60:103727.
   PubMed Web of Science ®Google Scholar
• Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021;20:762–772.
   PubMed Web of Science ®Google Scholar
• Banwell B, Bennett J, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): international MOGAD Panel Criteria. Lancet Neurol. In Press .
   Google Scholar
• Misu T, Höftberger R, Fujihara K, et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol. 2013;125:815–827.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–477.
   PubMed Web of Science ®Google Scholar
• Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007;69:2221–2231.
   PubMed Web of Science ®Google Scholar
• Nesargikar PN, Spiller B, Chavez R. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol (Bp). 2012;2:103–111.
   PubMedGoogle Scholar
• Bennett JL, O’Connor KC, Bar-Or A, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2:e104.
   PubMed Web of Science ®Google Scholar
• Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020;7:e841.
   PubMed Web of Science ®Google Scholar
• Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108:3701–3706.
   PubMed Web of Science ®Google Scholar
• Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4:e311.
   PubMed Web of Science ®Google Scholar
• Piatek P, Domowicz M, Lewkowicz N, et al. C5a-preactivated neutrophils are critical for autoimmune-induced astrocyte dysregulation in neuromyelitis optica spectrum disorder. Front Immunol. 2018;9:1694.
   PubMed Web of Science ®Google Scholar
• Giglhuber K, Berthele A. Adverse Events in NMOSD Therapy. Int J Mol Sci. 2022;23:4154.
   PubMed Web of Science ®Google Scholar
• Giovannelli J, Ciron J, Cohen M, et al. A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. Ann Clin Transl Neurol. 2021;8:2025–2037.
   PubMed Web of Science ®Google Scholar
• Jeong IH, Park B, Kim SH, et al. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler. 2016;22:329–339.
   PubMed Web of Science ®Google Scholar
• Voge NV, Alvarez E. Monoclonal antibodies in multiple sclerosis: present and future. Biomedicines. 2019;7:20.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Zhang I, Kielhorn A, et al. Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin g-positive neuromyelitis optica spectrum disorder. Neurol Ther. 2022;11:123–135.
   PubMed Web of Science ®Google Scholar
• Collongues N, de Seze J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord. 2016;9:180–188.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chang H, Zhang X, et al. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis. Mult Scler Relat Disord. 2021;50:102843.
   PubMed Web of Science ®Google Scholar
• Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020. 19: 298–306.
   PubMed Web of Science ®Google Scholar
• Tahara M, Oeda T, Okada K, et al. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): b cell monitoring-based administration. Mult Scler Relat Disord. 2022;60:103730.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou J, Li Y, et al. Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2021;14:17562864211056710.
   Web of Science ®Google Scholar
• Kim SH, Park NY, Kim KH, et al. Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-Year real-life experience. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1179.
   PubMed Web of Science ®Google Scholar
• Perriguey M, Maarouf A, Stellmann JP, et al. Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1115.
   PubMed Web of Science ®Google Scholar
• Kim SH, Huh SY, Jang H, et al. Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder. Eur J Neurol. 2020;27:1546–1555.
   PubMed Web of Science ®Google Scholar
• Smith JB, Hellwig K, Fink K, et al. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020;7.
   Web of Science ®Google Scholar
• Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of fcgr3a polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72:989–995.
   PubMed Web of Science ®Google Scholar
• Lindsey JW, Meulmester KM, Brod SA, et al. Variable results after rituximab in neuromyelitis optica. J Neurol Sci. 2012;317:103–105.
   PubMed Web of Science ®Google Scholar
• Nakashima I, Takahashi T, Cree BA, et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci. 2011;18:997–998.
   PubMed Web of Science ®Google Scholar
• Araki M. Blockade of IL-6 signaling in neuromyelitis optica. Neurochem Int. 2019;130:104315.
   PubMed Web of Science ®Google Scholar
• Li T, Zhang L-J, Zhang Q-X, et al. Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab. J Neuroimmunol. 2018;316:107–111.
   PubMed Web of Science ®Google Scholar
• Kim SH, Hyun JW, Kim HJ. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder. Neurochem Int. 2019;130:104347.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68:1412–1420.
   PubMedGoogle Scholar
• Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125:232–239.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Nakashima I. Efficiency of antibody therapy in demyelinating diseases. Int Immunol. 2017;29:327–335.
   PubMed Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394:1352–1363.
   PubMed Web of Science ®Google Scholar
• Cree BA, Bennett JL, Kim HJ, et al. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Mult Scler. 2021;27:2052–2061.
   PubMed Web of Science ®Google Scholar
• Rensel M, Zabeti A, Mealy MA, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ≥4 years in the N-MOmentum trial. Mult Scler. 2022;28:925–932.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Inebilizumab: first Approval. Drugs. 2020;80:1259–1264.
   PubMedGoogle Scholar
• Flanagan EP, Levy M, Katz E, et al. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Mult Scler Relat Disord. 2022;57:103352.
   PubMed Web of Science ®Google Scholar
• Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014;5:491.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol. 2004;4:386–391.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Masuda H, et al. Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: a special focus on neuromyelitis optica. Clin Chim Acta. 2017;469:144–149.
   PubMed Web of Science ®Google Scholar
• Lotan I, Charlson RW, Ryerson LZ, et al. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;39:101920.
   PubMed Web of Science ®Google Scholar
• Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72:756–763.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19:391–401.
   PubMed Web of Science ®Google Scholar
• Carreón Guarnizo E, Hernández Clares R, Castillo Triviño T, et al. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. Neurologia (Engl Ed). 2022;37:178–183.
   PubMed Web of Science ®Google Scholar
• Igawa T, Ishii S, Tachibana T, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010;28:1203–1207.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:2114–2124.
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19:402–412.
   PubMed Web of Science ®Google Scholar
• Kleiter I, Traboulsee A, Palace J, et al. Long-term efficacy of satralizumab in aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): results from the open-label extension periods of SAkuraSky and SAkuraStar (S25.009). Neurology. 2022;98(Suppl.18):1349.
   Google Scholar
• Greenberg B, De Seze J, Saiz A, et al. Long-term Safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD): results from the phase 3 SAkuraSky and SAkuraStar studies (S25.010). Neurology. 2022;98(Suppl.18):1354.
   Google Scholar
• Heo YA. Satralizumab: first Approval. Drugs. 2020;80:1477–1482.
   PubMedGoogle Scholar
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614–625.
   PubMed Web of Science ®Google Scholar
• Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33:1389–1401.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Fujihara K, Palace J, et al. Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension. Mult Scler. 2022;28:480–486.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Fujihara K, Palace J, et al. Long-Term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol. 2021;89:1088–1098.
   PubMed Web of Science ®Google Scholar
• Giglhuber K, Berthele A. Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy. 2020;12:1053–1066.
   PubMed Web of Science ®Google Scholar
• Brod SA. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult Scler Relat Disord. 2020;46:102538.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kulasekararaj AG. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Biol Ther. 2020;20:227–237.
   PubMed Web of Science ®Google Scholar
• Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13:e0195909.
   PubMed Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133:530–539.
   PubMed Web of Science ®Google Scholar
• Paul F, Pittock S, Barnett M, et al. A phase 3 study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. 8th Congress of the European Academ of Neurology. 25-28 June 2022. Vienna, Austria.
   Google Scholar
• Costello F, Burton JM. Contemporary management challenges in seropositive NMOSD. J Neurol. 2022;269:5674–5681.
   PubMed Web of Science ®Google Scholar
• Li R, Li C, Huang Q, et al. Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation. Eur J Neurol. 2022;29:2792–2800.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Zekeridou A, Weinshenker BG. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials. Nat Rev Neurol. 2021;17:759–773.
   PubMed Web of Science ®Google Scholar
• Luo J, Yu J, Sui Z, et al. Comparison on the effect of seven drugs to prevent relapses of neuromyelitis optica spectrum disorders: a modeling analysis of literature aggregate data. Int Immunopharmacol. 2022;110:109004.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.
   PubMed Web of Science ®Google Scholar
• Valencia-Sanchez C, Wingerchuk DM. Emerging targeted therapies for neuromyelitis optica spectrum disorders. BioDrugs. 2021;35:7–17.
   PubMed Web of Science ®Google Scholar
• Tugizova M, Vlahovic L, Tomczak A, et al. New therapeutic landscape in neuromyelitis optica. Curr Treat Options Neurol. 2021;23:13.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
   PubMed Web of Science ®Google Scholar
• Kıyat-Atamer A, Ekizoğlu E, Tüzün E, et al. Long-term MRI findings in neuromyelitis optica: seropositive versus seronegative patients. Eur J Neurol. 2013;20:781–787.
   PubMed Web of Science ®Google Scholar
• Tenembaum S, Yeh EA. Pediatric NMOSD: a review and position statement on approach to work-up and diagnosis. Front Pediatr. 2020;8:339.
   PubMed Web of Science ®Google Scholar
• Baghbanian SM, Asgari N, Sahraian MA, et al. A comparison of pediatric and adult neuromyelitis optica spectrum disorders: a review of clinical manifestation, diagnosis, and treatment. J Neurol Sci. 2018;388:222–231.
   PubMed Web of Science ®Google Scholar
• Ferilli MAN, Paparella R, Morandini I, et al. Pediatric neuromyelitis optica spectrum disorder: case series and literature review. Life (Basel). 2021;12:19.
   PubMed Web of Science ®Google Scholar
• Magraner MJ, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia. 2013;28:65–72.
   PubMed Web of Science ®Google Scholar
• Viswanathan S, Wong AH, Quek AM, et al. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. J Neuroimmunol. 2015;282:92–96.
   PubMed Web of Science ®Google Scholar
• Abboud H, Zheng C, Kar I, et al. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: relevance to the COVID-19 pandemic. Mult Scler Relat Disord. 2020;44:102249.
   PubMed Web of Science ®Google Scholar
• Kim W, Kim SH, Nakashima I, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012;78:1264–1267.
   PubMed Web of Science ®Google Scholar
• Tong Y, Liu J, Yang T, et al. Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis. Mult Scler Relat Disord. 2018;25:61–65.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (Baltimore). 2019;98:e15944.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Shin K, John G, et al. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol. 2015;6:413–418.
   PubMedGoogle Scholar
• Carnero Contentti E, López PA, Rojas JI. Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients. Expert Opin Emerg Drugs. 2022;27:91–98.
   PubMed Web of Science ®Google Scholar